Evolve BioSystems announces investment from Cargill and Manna Tree for infant gut health probiotic

By Jim Cornall contact

- Last updated on GMT

Evolve BioSystems manufactures Evivo, a proprietary probiotic proven to resolve infant gut dysbiosis, or Newborn Gut Deficiency.
Evolve BioSystems manufactures Evivo, a proprietary probiotic proven to resolve infant gut dysbiosis, or Newborn Gut Deficiency.

Related tags: Probiotics, microbiome, infant health, Gut health

US microbiome company Evolve BioSystems has announced that it completed a first close in a $55m Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health.

The new capital will be used to help the company continue commercializing a next generation of probiotic capable of addressing a widespread deficiency in the infant gut microbiome.

"We are thrilled to announce our newest investors as we continue our quest to address this health crisis in newborns,"​ said Timothy Brown, CEO of Evolve BioSystems.

"Our research found that more than 90% of infants in the US are missing the critical bacteria, Bifidobacterium longum subsp. infantis (B. infantis), which is widely documented as a key component of the infant gut microbiome. The financial support announced today, which includes strong continued support from our earlier investors, will help continue our mission to make a healthier future for our children during infancy and beyond."

Evolve BioSystems manufactures Evivo, a proprietary probiotic proven to resolve infant gut dysbiosis, or Newborn Gut Deficiency. Evivo is comprised of activated B. infantis​ EVC001, which studies have shown guides critical development of infants' digestive and immune systems.

Evivo restores this missing bacterium to the infant gut microbiome, reducing potentially pathogenic bacteria by 80% as well as significantly reducing intestinal inflammation. These pathogens are linked to higher risk of both short- and long-term health issues including colic, diaper rash, eczema, asthma, allergies and Type 1 Diabetes.

"Evivo, Evolve BioSystem's innovative infant probiotic, has been proven to have a dramatic impact on the developing infant gut, and to guide long-term health trajectory. This round of financing will continue to raise consumer and health care practitioner awareness, while supporting continued research and development. We are proud to partner with innovators like Tim and the entire Evolve team who are at the forefront of food and biotechnology,"​ said Gabrielle "Ellie" Rubenstein, co-founder and CEO of Manna Tree.

"This important investment is at the very core of our mission at Manna Tree - investing in human health."

The health benefits of Evivo are documented through numerous clinical studies and peer-reviewed publications. The investments of Manna Tree and Cargill come on the heels of the most recent breakthrough in the Evolve research, the U.S. Microbiome Survey, recently published in Scientific Reports. The research shows that nine out of ten US infants are suffering from Newborn Gut Deficiency, increasing risk to early infant health and development. The study is the largest to date to benchmark the widespread levels of potential pathogenic bacteria in U.S. infants and the substantial deficiency of B. infantis​.

"Evolve BioSystem's Evivo has the potential to be a highly distinctive probiotic for infants and we are delighted to work with them to scale its impact,"​ said Chuck Warta, president of Cargill's health technologies business.

"Our goal is to help humans live more healthy days right from the start. Together, we can harness our respective expertise and knowledge in nutrition, digestive and immune health to bring next generation ingredient solutions to our customers."

Through its collaboration with the Bill & Melinda Gates Foundation, Evolve BioSystems is currently involved in a clinical trial at the International Centre for Diarrheal Disease Research in Bangladesh to assess the impact of Evivo on infants who have been diagnosed with severe acute malnutrition.

As part of the investment, Cargill and Manna Tree will serve as lead investors and join the company's board of directors. Other Evolve BioSystems investors in this round include Horizons Ventures, Johnson & Johnson Innovation – JJDC, Inc., Spruce Capital Partners, Acre Venture Partners and Bow Capital. Evolve was spun-off from the Foods for Health Institute (FFHI) at the University of California, Davis in 2014.

Related topics: Ingredients, Nutritionals, Functional Dairy

Related news

comments

Post your comment

We will not publish your email address on the website

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Follow us

Products

View more

Webinars